Adhera Therapeutics Inc (ATRX)
Adhera Therapeutics, Inc. is a biotechnology company listed on OTC Markets as common stock under the ticker ATRX. The company focuses on the discovery, development, and commercialization of small molecule drug candidates. Its pipeline includes MLR-1019, which is being developed for Parkinson’s disease, and MLR-1023, which is being developed for Type 1 diabetes. The company was previously known as Marina Biotech, Inc. and adopted its current name in October 2018. Adhera Therapeutics is based in Baton Rouge, Louisiana.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ATRX
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
1.162 K
|
—
|
—
|
—
|
—
|
—
|
—
|